|
|
 |
ORIGINAL ARTICLE |
|
Year : 2013 | Volume
: 17
| Issue : 8 | Page : 496-500 |
|
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the South India cohort of the A 1 chieve study
S Nallaperumal1, Johny Kannampilly2
1 Swamy Diabetes Centre, Chennai, Tamil Nadu, India 2 Department of Diabetology, Lakeshore Hospital and Research Center Ltd, Kadavanthra, Kochi, Kerala, India
Date of Web Publication | 27-Nov-2013 |
Correspondence Address: S Nallaperumal Swamy Diabetes Centre Chennai India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2230-8210.122095
Abstract | | |
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents. Materials and Methods: Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from South India. Results: A total of 9273 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (n = 7217), insulin detemir (n = 1001), insulin aspart (n = 734), basal insulin plus insulin aspart (n = 117) and other insulin combinations (n = 189). At baseline glycaemic control was poor for both insulin naïve (mean HbA 1 c: 9.2%) and insulin user (mean HbA 1 c: 9.1%) groups. After 24 weeks of treatment both the groups showed improvement in HbA 1 c (insulin naïve: −1.6%, insulin users: −1.3%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients. Conclusion: Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia. Keywords: A 1 chieve study, insulin analogues, South India, type 2 diabetes mellitus
How to cite this article: Nallaperumal S, Kannampilly J. Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the South India cohort of the A 1 chieve study. Indian J Endocr Metab 2013;17, Suppl S2:496-500 |
How to cite this URL: Nallaperumal S, Kannampilly J. Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the South India cohort of the A 1 chieve study. Indian J Endocr Metab [serial online] 2013 [cited 2021 Jan 16];17, Suppl S2:496-500. Available from: https://www.ijem.in/text.asp?2013/17/8/496/122095 |
Introduction | |  |
62.4 million Indians were reported to have type 2 diabetes mellitus (T2DM) putting India on the forefront of diabetic epidemic across globe. [1],[2] Fear of hypoglycaemia and gain in body weight act as barriers for initiation of insulin therapy. [3] Modern insulin analogues are a convenient new approach or tool to glycaemic control, associated with low number of hypoglycaemia and favourable weight change. [4] A 1 chieve, a multinational, 24-week, non-interventional study, assessed the safety and effectiveness of insulin analogues in people with T2DM (n = 66,726) in routine clinical care. [5] This short communication presents the results for patients enrolled from South India.
Materials and Methods | |  |
Please refer to editorial titled: The A 1 chieve study: Mapping the Ibn Battuta trail.
Results | |  |
A total of 9273 patients were enrolled in the study. The patient characteristics for the entire cohort divided as insulin-naïve and insulin users is shown in the [Table 1]. Glycaemic control at baseline was poor in this population. The majority of patients (77.8%) started on or were switched to biphasic insulin aspart. Other groups were insulin detemir (n = 1001), insulin aspart (n = 734), basal insulin plus insulin aspart (n = 117) and other insulin combinations (n = 189).
After 24 weeks of treatment, overall hypoglycaemic events reduced from 0.8 events/patient-year to 0.1 events/patient-year in insulin naive group and from 2.6 events/patient-year to 0.7 events/patient-year in insulin user group. The hypoglycaemia incidence in insulin naive group at 24 weeks was lower than that observed in insulin users at baseline. SADRs including major hypoglycaemic events did not occur in any of the study patients. Blood pressure decreased whereas overall lipid profile and quality of life improved at week 24 in the cohort [Table 2] and [Table 3].
All parameters of glycaemic control improved from baseline to study end in the total cohort [Table 4].
Biphasic insulin aspart ± OGLD
Of the total cohort, 7217 patients started on biphasic insulin aspart ± OGLD, of which 5995 (83.1%) were insulin naïve and 1222 (16.9%) were insulin users. After 24 weeks of starting or switching to biphasic insulin aspart, hypoglycaemic events reduced from 0.2 events/patient-year to 0.0 events/patient-year in insulin naïve group and from 2.2 events/patient-year to 0.1 events/patient-year in insulin users group. Body weight decreased and quality of life improved after 24 weeks of treatment [Table 5] and [Table 6].
All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin naïve and insulin user groups [Table 7]. | Table 7: Biphasic insulin aspart±oral glucose-lowering drug efficacy data
Click here to view |
Basal + insulin aspart ± OGLD
Of the total cohort, 117 patients started on basal + insulin aspart ± OGLD, of which 58 (49.6%) were insulin naïve and 59 (50.4%) were insulin users. After 24 weeks of starting or switching to biphasic insulin aspart, hypoglycaemic events reduced from 2.7 events/patient-year to 0.6 events/patient-year in insulin naïve group and from 4.9 events/patient-year to 1.4 events/patient-year in insulin users group. Body weight decreased and quality of life improved after 24 weeks [Table 8] and [Table 9].
All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to basal + insulin aspart ± OGLDs for both insulin naïve and insulin user groups [Table 10].
Insulin detemir ± OGLD
Of the total cohort, 1001 patients started on insulin detemir ± OGLD, of which 865 (86.4%) were insulin naïve and 136 (13.6%) were insulin users. After 24 weeks of starting or switching to biphasic insulin aspart, hypoglycaemic events reduced from 1.0 events/patient-year to 0.2 events/patient-year in insulin naïve group and from 2.3 events/patient-year to 0.7 events/patient-year in insulin users group. A decrease in body weight and improvement in quality of life was observed at the end of the study [Table 11] and [Table 12].
All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir ± OGLDs for both insulin-naïve and insulin user groups [Table 13].
Insulin aspart ± OGLD
Of the total cohort, 734 patients started on insulin aspart ± OGLD, of which 583 (79.4%) were insulin naïve and 151 (20.6%) were insulin users. After 24 weeks of starting or switching to insulin aspart, overall hypoglycaemia decreased from 0.6 events/patient-year to 0.0 events/patient-year in insulin naive group and from 2.7 events/patient-year to 0.5 events/patient-year in insulin users group. A decrease in body weight and improvement in quality of life was noted at 24 weeks [Table 14] and [Table 15].
All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin aspart ± OGLDs for both insulin naïve and insulin user groups [Table 16].
Conclusion | |  |
Our study reports improved glycaemic control (HbA 1 c, FPG, PPPG) and quality of life following 24 weeks of treatment with any of the insulin analogues (Biphasic insulin aspart; basal + insulin aspart; insulin detemir; insulin aspart) with or without OGLD. SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients after 24 week of treatment. A small weight reduction was noted for all four regimens. Though the findings are limited by number of patients, still the trend indicates that insulin analogues can be considered effective and possess a safe profile for treating type 2 diabetes in South India.
References | |  |
1. | Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.  |
2. | Shetty P. Public health: India's diabetes time bomb. Nature 2012;485:S14-6.  |
3. | Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26 Suppl 3:S18-24.  |
4. | Hirsch IB. Insulin analogues. N Engl J Med 2005;352:174-83.  |
5. | Shah SN, Litwak L, Haddad J, Chakkarwar PN, Hajjaji I. The A1chieve study: A 60 000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice. Diabetes Res Clin Pract 2010;88 Suppl 1:S11-6.  |
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7], [Table 8], [Table 9], [Table 10], [Table 11], [Table 12], [Table 13], [Table 14], [Table 15], [Table 16]
This article has been cited by | 1 |
Impact of adopting the 2013 World Health Organization criteria for diagnosis of gestational diabetes in a multi-ethnic Asian cohort: a prospective study |
|
| Claudia Chi,See Ling Loy,Shiao-Yng Chan,Cherie Choong,Shirong Cai,Shu E. Soh,Kok Hian Tan,Fabian Yap,Peter D. Gluckman,Keith M. Godfrey,Lynette Pei-Chi Shek,Jerry Kok Yen Chan,Michael S. Kramer,Yap-Seng Chong | | BMC Pregnancy and Childbirth. 2018; 18(1) | | [Pubmed] | [DOI] | | 2 |
Comparison of Diagnostic Accuracy of Non-fasting DIPSI and HbA1c with Fasting WHO Criteria for Diagnosis of Gestational Diabetes Mellitus |
|
| Pikee Saxena,Puja Verma,Binita Goswami | | The Journal of Obstetrics and Gynecology of India. 2017; | | [Pubmed] | [DOI] | | 3 |
Prevalence of Gestational Diabetes Mellitus in urban and rural Tamil Nadu using IADPSG and WHO 1999 criteria (WINGS 6) |
|
| Balaji Bhavadharini,Manni Mohanraj Mahalakshmi,Ranjit Mohan Anjana,Kumar Maheswari,Ram Uma,Mohan Deepa,Ranjit Unnikrishnan,Harish Ranjani,Sonak D Pastakia,Arivudainambi Kayal,Lyudmil Ninov,Belma Malanda,Anne Belton,Viswanathan Mohan | | Clinical Diabetes and Endocrinology. 2016; 2(1) | | [Pubmed] | [DOI] | | 4 |
Hemoglobin A1c as screening for gestational diabetes mellitus in Nordic Caucasian women |
|
| Ingrid Hov Odsæter,Arne Åsberg,Eszter Vanky,Siv Mørkved,Signe Nilssen Stafne,Kjell Åsmund Salvesen,Sven Magnus Carlsen | | Diabetology & Metabolic Syndrome. 2016; 8(1) | | [Pubmed] | [DOI] | | 5 |
Early third trimester maternal response to glucose challenge and pregnancy outcome in Chinese women—relationship between upper distribution level and recommended diagnostic criteria |
|
| M Y Du,R M Ma,T T-H Lao,Z Chen,H Xiao,Y Q Tian,B L Li,K Liang,L Zhang,M H Yang,J Li,H Li,R Yan,L Geng,W J Qi,H Y Li,J Xu,S Q Hu,G H Liang,J H Yu | | European Journal of Clinical Nutrition. 2015; | | [Pubmed] | [DOI] | | 6 |
HbA1c as screening for gestational diabetes mellitus in women with polycystic ovary syndrome |
|
| Ingrid Hov Odsæter,Arne Åsberg,Eszter Vanky,Sven Magnus Carlsen | | BMC Endocrine Disorders. 2015; 15(1) | | [Pubmed] | [DOI] | | 7 |
Gestational diabetes mellitus among Nordic Caucasian women: Prevalence and risk factors according to WHO and simplified IADPSG criteria |
|
| Ragnhild Helseth,Øyvind Salvesen,Signe N. Stafne,Siv Mørkved,Kjell A. Salvesen,Sven M. Carlsen | | Scandinavian Journal of Clinical & Laboratory Investigation. 2014; : 1 | | [Pubmed] | [DOI] | |
|
 |
 |
|